Somatostatin Receptor Imaging in NPC, EBV Related Cancers

Launched by NATIONAL CANCER CENTRE, SINGAPORE · Oct 13, 2022

Keywords

ClinConnect Summary

This clinical trial is looking into a specific type of cancer called nasopharyngeal cancer (NPC) and other cancers related to the Epstein-Barr virus (EBV). Researchers want to understand how many NPC patients have a high amount of somatostatin receptors, which are special proteins that might help target new treatments in the future. The study will also check for these receptors in other EBV-related cancers. If you or someone you know has locally advanced, metastatic, or recurrent NPC and is over 21 years old, you might be eligible to participate.

Participants will undergo imaging tests, including a type of scan called Ga-68 DOTATATE, to see how the somatostatin receptors are behaving in their cancer. This trial is currently recruiting patients, and it’s important to note that pregnant or breastfeeding women cannot take part. By joining this study, participants could contribute to understanding more about NPC and potentially help shape future treatments for themselves and others facing similar challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Locally advanced, metastatic or locally recurrent NPC that are going for FDG PET as part of their investigations
• • Patients that have gone for Ga-68 DOTATATE imaging before are eligible for repeat imaging
• • Histologically confirmed NPC
• • Above 21 years of age
• Exclusion Criteria:
• • Patients below 21 years of age
• • Pregnant and breast feeding ladies